论文部分内容阅读
目的:观察吉西他滨(Gemcitabine,GEM)联合顺铂(DDP)治疗多柔比星(ADM)及紫杉醇(Paclitaxel)耐药的晚期转移性乳腺癌的疗效及毒性。方法:30例既往使用ADM及Paclitaxel治疗后复发转移的晚期乳腺癌患者,采用吉西他滨联合顺铂治疗,2l d为1个周期,每2个周期评定疗效。结果:完全缓解(CR)2例,部分缓解(PR)18例,稳定(SD)7例,进展(PD)3例,总有效率为66.7%(20/30)。结论:GEM联合DDP治疗ADM及Paclitaxel耐药的晚期转移性乳腺癌疗效确切,毒性反应可耐受,值得临床应用。
Objective: To observe the efficacy and toxicity of Gemcitabine (GEM) combined with cisplatin (DDP) in the treatment of advanced metastatic breast cancer cells resistant to doxorubicin (ADM) and paclitaxel. Methods: Thirty patients with advanced breast cancer who had previously relapsed and metastasized with ADM and Paclitaxel were treated with gemcitabine combined with cisplatin. One cycle was performed on day 21 and the effect was evaluated every two cycles. Results: There were 2 cases of complete remission (CR), 18 cases of partial remission (PR), 7 cases of stable (SD) and 3 cases of progressive (PD). The total effective rate was 66.7% (20/30). Conclusion: GEM combined with DDP in the treatment of ADM and Paclitaxel-resistant advanced metastatic breast cancer has definite curative effect and tolerable toxicity response, which is worthy of clinical application.